Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida 32610, United States.
Department of Pathology and Laboratory Medicine, School of Medicine, Tulane University, New Orleans, Louisiana 70112, United States.
J Med Chem. 2024 Sep 12;67(17):15168-15198. doi: 10.1021/acs.jmedchem.4c00815. Epub 2024 Aug 27.
Yes-associated protein (YAP) is a key oncogene in the Hippo tumor suppression pathway, historically challenging to target due to its intrinsically disordered nature. Leveraging recent advances in high-throughput screening that identified several YAP binders, we employed proteolysis-targeting chimera technology to develop a series of YAP degraders. Utilizing NSC682769, a known YAP binder, linked with VHL ligand 2 or pomalidomide via diverse linkers, we synthesized degraders including . This degrader not only recruits the E3 ligase VHL for the rapid and sustained degradation of YAP but also effectively inhibits its nuclear localization, curtailing YAP/TEAD-mediated transcription in cancer cell lines such as NCI-H226 and Huh7. This dual action significantly diminishes YAP's oncogenic activity, contributing to the potent antiproliferative effects observed both in vitro and in a Huh7 xenograft mouse model. These results underscore the potential of PROTAC-mediated YAP degradation as a strategy for treating YAP-driven cancers.
Yes 相关蛋白 (YAP) 是 Hippo 肿瘤抑制通路中的关键致癌基因,由于其固有无序的性质,历史上难以成为靶向治疗的对象。利用最近在高通量筛选方面的进展,这些筛选方法鉴定了几种 YAP 结合物,我们采用蛋白水解靶向嵌合体技术开发了一系列 YAP 降解剂。我们利用已知的 YAP 结合物 NSC682769,通过不同的连接子与 VHL 配体 2 或泊马度胺相连,合成了包括在内的降解剂。这种降解剂不仅募集 E3 连接酶 VHL,使 YAP 快速而持续地降解,还能有效地抑制其核定位,从而阻断 YAP/TEAD 在 NCI-H226 和 Huh7 等癌细胞系中的介导转录。这种双重作用显著降低了 YAP 的致癌活性,导致在体外和 Huh7 异种移植小鼠模型中观察到的强烈抗增殖作用。这些结果强调了 PROTAC 介导的 YAP 降解作为治疗 YAP 驱动型癌症的一种策略的潜力。